Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 50.8
(-4.87%)
SEK 50.8
(-4.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -329.06 Million SEK | 2.02% |
| 2022 | -335.84 Million SEK | 13.16% |
| 2021 | -386.75 Million SEK | 8.66% |
| 2020 | -423.43 Million SEK | 14.49% |
| 2019 | -495.18 Million SEK | 8.67% |
| 2018 | -542.17 Million SEK | -242.55% |
| 2017 | -158.27 Million SEK | -68.76% |
| 2016 | -93.78 Million SEK | -111.18% |
| 2015 | -44.41 Million SEK | -4113.57% |
| 2014 | -1.05 Million SEK | -16.94% |
| 2013 | -901.29 Thousand SEK | -1771.74% |
| 2012 | -48.15 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -309.61 Million SEK | 5.91% |
| 2024 Q2 | -272.51 Million SEK | 11.99% |
| 2023 Q3 | -367.2 Million SEK | -22.01% |
| 2023 FY | -329.06 Million SEK | 2.02% |
| 2023 Q4 | -329.06 Million SEK | 10.39% |
| 2023 Q1 | -306.68 Million SEK | 8.68% |
| 2023 Q2 | -300.95 Million SEK | 1.87% |
| 2022 Q1 | -382.17 Million SEK | 1.18% |
| 2022 Q2 | -373.97 Million SEK | 2.15% |
| 2022 Q4 | -335.84 Million SEK | 8.82% |
| 2022 Q3 | -368.33 Million SEK | 1.51% |
| 2022 FY | -335.84 Million SEK | 13.16% |
| 2021 Q4 | -386.75 Million SEK | 0.92% |
| 2021 Q1 | -425.75 Million SEK | -0.55% |
| 2021 Q2 | -409.06 Million SEK | 3.92% |
| 2021 FY | -386.75 Million SEK | 8.66% |
| 2021 Q3 | -390.36 Million SEK | 4.57% |
| 2020 Q1 | -500.99 Million SEK | -1.17% |
| 2020 FY | -423.43 Million SEK | 14.49% |
| 2020 Q2 | -473.6 Million SEK | 5.47% |
| 2020 Q3 | -463.04 Million SEK | 2.23% |
| 2020 Q4 | -423.43 Million SEK | 8.55% |
| 2019 Q3 | -511.88 Million SEK | 5.11% |
| 2019 FY | -495.18 Million SEK | 8.67% |
| 2019 Q4 | -495.18 Million SEK | 3.26% |
| 2019 Q2 | -539.45 Million SEK | 0.2% |
| 2019 Q1 | -540.51 Million SEK | 0.31% |
| 2018 FY | -542.17 Million SEK | -242.55% |
| 2018 Q2 | -576.8 Million SEK | 0.74% |
| 2018 Q4 | -542.17 Million SEK | 4.34% |
| 2018 Q3 | -566.78 Million SEK | 1.74% |
| 2018 Q1 | -581.08 Million SEK | -267.14% |
| 2017 Q3 | -67.17 Million SEK | 11.98% |
| 2017 FY | -158.27 Million SEK | -68.76% |
| 2017 Q1 | -84.67 Million SEK | 9.72% |
| 2017 Q2 | -76.32 Million SEK | 9.86% |
| 2017 Q4 | -158.27 Million SEK | -135.61% |
| 2016 Q4 | -93.78 Million SEK | 0.0% |
| 2016 FY | -93.78 Million SEK | -111.18% |
| 2016 Q2 | -116.38 Million SEK | -362.06% |
| 2016 Q1 | 44.41 Million SEK | 200.0% |
| 2015 Q3 | -44.41 Million SEK | 0.0% |
| 2015 FY | -44.41 Million SEK | -4113.57% |
| 2015 Q1 | 1.05 Million SEK | 0.0% |
| 2015 Q4 | -44.41 Million SEK | 0.0% |
| 2014 FY | -1.05 Million SEK | -16.94% |
| 2013 FY | -901.29 Thousand SEK | -1771.74% |
| 2012 FY | -48.15 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -557.852% |
| Ziccum AB (publ) | -2.13 Million SEK | -15298.409% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -1626.464% |
| BioArctic AB (publ) | -606.58 Million SEK | 45.752% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -558.998% |
| Mendus AB (publ) | -96.29 Million SEK | -241.728% |
| Genovis AB (publ.) | -43.94 Million SEK | -648.877% |
| Intervacc AB (publ) | -88.16 Million SEK | -273.258% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 1704.408% |
| Active Biotech AB (publ) | -33.2 Million SEK | -891.157% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 718.274% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -735.57% |
| Aptahem AB (publ) | 2.9 Million SEK | 11413.321% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 1.366% |
| Kancera AB (publ) | -45.69 Million SEK | -620.179% |
| Fluicell AB (publ) | -2.76 Million SEK | -11809.663% |
| Saniona AB (publ) | 40.44 Million SEK | 913.568% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -930.676% |
| Biovica International AB (publ) | -58.73 Million SEK | -460.233% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -627.744% |
| AcouSort AB (publ) | -23.98 Million SEK | -1271.9% |
| Xintela AB (publ) | -7.8 Million SEK | -4113.907% |
| Abliva AB (publ) | -57.24 Million SEK | -474.885% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | -69.011% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -300.311% |
| OncoZenge AB (publ) | -12.62 Million SEK | -2506.035% |
| Amniotics AB (publ) | -5.63 Million SEK | -5742.756% |
| 2cureX AB (publ) | -13.4 Million SEK | -2355.152% |
| CombiGene AB (publ) | -101.44 Million SEK | -224.393% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -15127.395% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 6193.778% |
| Camurus AB (publ) | -1.16 Billion SEK | 71.762% |
| Corline Biomedical AB | -17.01 Million SEK | -1834.305% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -292.945% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -138.197% |
| I-Tech AB | -83.26 Million SEK | -295.215% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 344.279% |
| Cyxone AB (publ) | -16.67 Million SEK | -1873.989% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -488.813% |
| Biosergen AB | -1.88 Million SEK | -17375.518% |
| Cantargia AB (publ) | -139.74 Million SEK | -135.471% |
| NextCell Pharma AB | -46.79 Million SEK | -603.269% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -154.113% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -1019.914% |
| Nanologica AB (publ) | -9.38 Million SEK | -3405.156% |
| SynAct Pharma AB | -61.75 Million SEK | -432.828% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -1436.605% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -2387.41% |
| LIDDS AB (publ) | -13.51 Million SEK | -2335.346% |
| Lipum AB (publ) | -8.46 Million SEK | -3787.348% |
| BioInvent International AB (publ) | -236.3 Million SEK | -39.255% |
| Alzinova AB (publ) | -21.22 Million SEK | -1450.287% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -391.727% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -6251.459% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -292.954% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -35551.571% |
| Simris Alg AB (publ) | 85.07 Million SEK | 486.793% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -300.877% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 298.139% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -1482.571% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -10972.14% |